Clinical Trials Browser

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Postoperative Complications, Rectal Neoplasms

Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Neurotoxicity Syndromes

Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Rectal Neoplasms

Adenocarcinoma, Colonic Neoplasms, Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Rectal Neoplasms

Clinical Trials

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer

Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

OMEGA

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

BRANCH

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

AXEBEAM

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

INOVA

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer

Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer

Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer

Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy

High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer

Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer